TB-500
Thymosin Beta-4 Fragment • Also called TB500, Thymosin Beta-4, Thymosin Beta 4, Thymosin Beta 4 Fragment
TB-500 is marketed for recovery and tissue regeneration, but it remains outside routine lawful compounding pathways.
Current status
Restricted
Recovery-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Frequently discussed alongside BPC-157 in reform conversations, though current federal status remains restrictive.
Primary Use
Recovery-related interest
Also searched as
TB500, Thymosin Beta-4, Thymosin Beta 4, Thymosin Beta 4 Fragment
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 29, 2023
Current status signal recorded: Included among peptides treated as difficult to justify for compounding..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when TB-500 status changes
State-specific notes
California
Wellness clinics rarely obtain it from compliant pharmacies.
New York
Sourcing tends to disappear quickly after enforcement shifts.